{"name":"Wuhan Createrna Science and Technology Co., Ltd","slug":"wuhan-createrna-science-and-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Eculizumab Injection","genericName":"Eculizumab Injection","slug":"eculizumab-injection","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"MY008211A tablets","genericName":"MY008211A tablets","slug":"my008211a-tablets","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Eculizumab Injection","genericName":"Eculizumab Injection","slug":"eculizumab-injection","phase":"phase_3","mechanism":"Eculizumab is a monoclonal antibody that inhibits the complement protein C5, blocking the formation of the membrane attack complex and reducing complement-mediated cell destruction.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)","Atypical hemolytic uremic syndrome (aHUS)","Generalized myasthenia gravis (gMG)","Neuromyelitis optica spectrum disorder (NMOSD)"],"catalyst":""},{"name":"MY008211A tablets","genericName":"MY008211A tablets","slug":"my008211a-tablets","phase":"phase_3","mechanism":"MY008211A tablets' mechanism is unknown.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPUV9KRVY2dUNwb1pWWnMzaVllbFdrVlhRYkVoczdySGxDc3VSWU0zTTZBSGxsU21sUk53RldoTHV3V1V5S0RZSUxiTVBjbDlvdml3SEdFTUZ5bXZtNGx4Qlc1QTBaZm9XNmJoZDlaTWZIaGtuOUxMcGd6VnVwSGItejFKVmY2R0hFNkM5NlBWTFFlNmFKUE42dVZHeGI0SkpUckRMcHhhMlBvZGRvQlZwWGxtMVEzZlBlcGtEX2JwRk5NcVgwUEVNVFdaTXhSQzhXdlhJRm15c0hOZmpFZ0RYWDJ6b3h4NzBlU3pRTVZ4QW51enZnSXJsVVdQOHVOZw?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOUWgzamdSaVNlOE1TclRTME9HMDlBejFGeXloNFIzOGx2RjN5ekM4MUR1TUhMMmIzdThYZXdRLUpmYldMRnhVMGJZVF9sLUN0NVlJTW5sQTZ6WEhvN2M3dzhaMW11ZEYwdVRhWlZBWFZKZEJBN2dkOWJvVFVFdGtWRmpwSnZpdWRVUVZoZHkxa2dXejFnM1QzMQ?oc=5","date":"2026-03-30","type":"trial","source":"openPR.com","summary":"IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+ - openPR.com","headline":"IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}